Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
21 Jun 2023
AMP945 International Nonproprietary Name Narmafotinib
19 Jun 2023
Amplia AGM to be held Thursday 24 August 2023
31 May 2023
Key to Corporate Governance Disclosures
30 May 2023
2023 Corporate Governance Statement
30 May 2023
Annual Report to Shareholders
29 May 2023
AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
23 May 2023
Grant to collaborate with CSIRO Supplementary Announcement
22 May 2023
Amplia receives grant to collaborate with CSIRO
09 May 2023
ACCENT Trial Recruitment Progress
26 Apr 2023
Quarterly Activities and Cashflow Reports - March 23 Qtr
Previous
1
2
3
4
Next
